amantadine ER for dyskinesia
Selected indexed studies
- Extended-Release Amantadine for Levodopa-Induced Dyskinesia. (Expert Rev Neurother, 2019) [PMID:30892103]
- International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease. (Mov Disord, 2018) [PMID:29570866]
- The role of extended-release amantadine for the treatment of dyskinesia in Parkinson's disease patients. (Neurodegener Dis Manag, 2018) [PMID:29564954]
_Worker-drafted node — pending editorial review._
Connections
amantadine ER for dyskinesia is a side effect of
Sources
- Potential utility of amantadine DR/ER in persons with Parkinson's disease meeting 5-2-1 criteria for device aided therapy. (2022) pubmed
- Extended-Release Amantadine for Levodopa-Induced Dyskinesia. (2019) pubmed
- International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease. (2018) pubmed
- Amantadine ER (Gocovri(®)) Significantly Increases ON Time Without Any Dyskinesia: Pooled Analyses From Pivotal Trials in Parkinson's Disease. (2021) pubmed
- The role of extended-release amantadine for the treatment of dyskinesia in Parkinson's disease patients. (2018) pubmed
- Amantadine Extended-Release (GOCOVRI(™)): A Review in Levodopa-Induced Dyskinesia in Parkinson's Disease. (2018) pubmed
- Efficacy and safety of amantadine for the treatment of L-DOPA-induced dyskinesia. (2018) pubmed
- Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson's Disease. (2018) pubmed
- Recent Clinical Advances in Pharmacotherapy for Levodopa-Induced Dyskinesia. (2019) pubmed
- Immediate-release/extended-release amantadine (OS320) to treat Parkinson's disease with levodopa-induced dyskinesia: Analysis of the randomized, controlled ALLAY-LID studies. (2022) pubmed